Arteriosclerosis News and Research

RSS

Arteriosclerosis is a general term describing any hardening (and loss of elasticity) of medium or large arteries.

Benefits of wartime camaraderie extend far beyond the battlefield: Study of U.S. Civil War veterans

Veterans who served in military units characterized by a strong esprit de corps were much less likely decades later to die of a stroke or heart condition than veterans from less cohesive companies, two UCLA economists have found.

19 Feb 2010

Anti-PC antibody linked to reduced risk of arteriosclerosis

The chances of suffering a stroke are linked to the presence of a certain type of antibody in the immune system, a new study from Karolinska Institutet shows. The researchers hope to be able to develop a vaccine that can mobilise the body's own defence against arteriosclerosis and stroke.

12 Feb 2010

Discovery presents a vital step towards efficient treatment of vascular injuries

Hyperglycemia starts a complex chain of events that damages blood vessels and cause cardiovascular disease. Scientists at Lund University Diabetes Centre (LUDC) have now been able to demonstrate why this happens, as well as how the destructive chain can be broken.

7 Dec 2009

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

16 Nov 2009

Shire announces findings from Phase 3 study data with Vyvanse

Shire plc, the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

13 Nov 2009

Online patient support program for ADHD patients taking Vyvanse Capsules CII medication

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the re-launch of FOCUS (http://www.vyvanseFOCUS.com), a free, online patient support program for adults taking once-daily Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), and the only online, branded personalized patient support program providing tips and tools for adults diagnosed with ADHD taking a prescription medication.

11 Nov 2009

Shire to present key data on ADHD treatments at national psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

31 Oct 2009

Michigan residents sue State over denied access to dental healthcare

In a move aimed at forcing the State of Michigan and the Legislature to protect the rights of Michigan's most vulnerable population, including the developmentally disabled and those with minimal financial resources, a lawsuit was filed in federal court against the Granholm Administration. A class of more than 400,000 at-risk Michigan residents is suing the State for failing to uphold its legal obligations with regard to funding certain dental care services under the federal Medicaid program.

30 Oct 2009

Shire's ADHD treatment data to be presented at the Honolulu psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV(TM) (guanfacine) Extended Release Tablets, Vyvanse®( ) (lisdexamfetamine dimesylate) Capsules CII, and Daytrana®( ) (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

30 Oct 2009

Shire announces new pharmacokinetic data of ADHD medication

Shire plc, the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally.

23 Oct 2009

New drug promises to reduce damage from a heart attack

Research into a new drug by Australian heart experts has found that it can dramatically reduce heart muscle damage after a heart attack.

28 Jul 2009

New drug may reduce heart attack damage

A novel drug that targets a master disease-causing gene can dramatically reduce heart muscle damage after a heart attack and may lead to significantly improved patient outcomes, researchers at the University of New South Wales (UNSW) have shown.

22 Jul 2009

Urine proteome pattern may predict coronary artery disease

Proteome analysis, a screening requiring only a patient's urine specimen, shows promise as a reliable and noninvasive way to diagnose atherosclerosis and coronary artery disease in the future, according to research presented at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2009.

30 Apr 2009

Better targeting of stem cells as medication

Up till now it has not been possible to control stem cells in such a way that they grow into new blood vessels outside the body, or - when injected into an organ - lead to the creation of new small blood vessels and tissue repair.

26 Apr 2009

Shire withdraws European application for Daytrana (Methylphenidate Transdermal System)

Shire plc has announced that it has decided to withdraw the European Marketing Authorization Application (MAA) for Daytrana (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

16 Mar 2009

Dendritic cells as a new player in arteries and heart valves

In 1973, Ralph M. Steinman launched a new scientific discipline when he published his discovery of the dendritic cell, an odd-shaped player in the immune system.

16 Feb 2009

Pathologically elevated blood fat levels in obesity: Researchers discover molecular causes

Scientists at the German Cancer Research Center have discovered a mechanism in liver metabolism that is responsible for pathologically elevated blood fat levels found in severe metabolic disorders.

9 Feb 2009

Single letter in the human genome points to risk for high cholesterol

Write out every letter in the human genome, one A, C, T or G per millimeter, and the text would be 1,800 miles long, roughly the distance from New York to Colorado.

16 Dec 2008

Discovery of gene mutation that appears to help prevent heart disease

Researchers at the University of Maryland School of Medicine in Baltimore have discovered a novel gene mutation among the Old Order Amish population that significantly reduces the level of triglycerides in the blood and appears to help prevent cardiovascular disease.

12 Dec 2008

Protein could prevent blocked arteries

For the first time, researchers have found that a modified form of a naturally occurring protein, N-cadherin, could prevent blocked arteries. Blocked arteries are a major cause of heart attacks and strokes.

10 Dec 2008